ATCC uses CRISPR/Cas9 gene editing to introduce defined, disease-relevant genetic alterations into authenticated cell lines from our collection. Single guide RNAs (sgRNAs) direct Cas9 to the target genomic region, where the desired edit is introduced. Following transfection, cells are isolated, expanded, and screened to identify successfully edited clones. The resulting isogenic cell lines undergo rigorous genetic and functional characterization to confirm the intended modification and evaluate its biological effects. 

ATCC isogenic cell lines undergo rigorous validation to confirm that the intended genetic modification has been accurately introduced and that the resulting phenotype is biologically relevant. For genetic and transcript-level validation, ATCC uses Sanger sequencing, next-generation sequencing (NGS), PCR, and RT-PCR to verify the presence and expression of the targeted edit. For protein expression and functional validation, ATCC employs Western blot analysis (when appropriate), drug response testing, and other biofunctional assays to confirm that the engineered mutation produces the expected biological effects. This multi-level validation approach helps ensure that researchers can confidently use ATCC isogenic models to study disease mechanisms, drug response, and therapeutic resistance. 

ATCC offers isogenic cell lines engineered with clinically relevant genetic alterations involved in cancer development and therapeutic resistance. Available models include KRAS (G13D, G12D), NRAS (Q61K), BRAF (V600E), PIK3CA (E545K), and EGFR (C797S) mutations, as well as oncogenic fusions such as EML4-ALK, TPM3-NTRK1, and GOPC-ROS1. These precisely edited cell lines are available across several tumor backgrounds and can be used for drug discovery, target validation, biomarker research, and studies of resistance mechanisms. Some models are also available as Luc2-labeled variants for bioluminescent imaging applications.

ATCC isogenic cell lines are generated from authenticated parental cell lines and are designed to differ only by a defined genetic alteration. Because the parental and engineered cell lines share the same genetic background, they provide a controlled system for studying the biological and functional effects of specific mutations, gene fusions, and resistance-associated variants. The table below lists the parental cell lines from which each ATCC isogenic model was derived.

Yes. Isogenic cell lines are most powerful when used alongside their matched parental cell lines. Because both models share the same genetic background except for the engineered alteration, researchers can more accurately attribute observed differences in cellular behavior, pathway activity, biomarker expression, or drug response to the genetic change under investigation. This controlled comparison helps support more confident interpretation of experimental results.